- Home
- CRAC vs VYGR Comparison
CRAC vs VYGR Comparison
Compare CRAC & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRAC | VYGR |
|---|---|---|
| Founded | 2025 | 2013 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 214.3M | 226.8M |
| IPO Year | 2025 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CRAC | VYGR |
|---|---|---|
| Price | $9.94 | $3.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 65.4K | ★ 386.3K |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $31,316,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $71.78 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.04 | $2.65 |
| 52 Week High | $10.65 | $6.27 |
Technical Indicators
Market Signals| Indicator | CRAC | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 44.40 |
| Support Level | N/A | $3.82 |
| Resistance Level | N/A | $4.26 |
| Average True Range (ATR) | 0.00 | 0.21 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 22.37 |
Price Performance
Historical ComparisonAbout CRAC Crown Reserve Acquisition Corp. I Class A Ordinary Shares
Crown Reserve Acquisition Corp I is a blank check company.
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.